Laboratory Corporation of America Holdings (NYSE:LH) insider F Samuel Eberts III sold 31,500 shares of the business’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $155.22, for a total transaction of $4,889,430.00. Following the transaction, the insider now owns 31,894 shares in the company, valued at $4,950,586.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Laboratory Corporation of America Holdings (LH) opened at 156.87 on Friday. Laboratory Corporation of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22. The firm has a market cap of $15.97 billion, a PE ratio of 21.97 and a beta of 0.94. The company’s 50-day moving average is $156.33 and its 200-day moving average is $146.37.

Laboratory Corporation of America Holdings (NYSE:LH) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The firm had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.47 billion. During the same quarter in the previous year, the firm earned $2.36 earnings per share. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. Analysts forecast that Laboratory Corporation of America Holdings will post $9.51 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Laboratory Corporation of America Holdings (LH) Insider Sells $4,889,430.00 in Stock” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/01/insider-selling-laboratory-corporation-of-america-holdings-lh-insider-sells-4889430-00-in-stock.html.

A number of hedge funds have recently added to or reduced their stakes in LH. Acrospire Investment Management LLC raised its stake in Laboratory Corporation of America Holdings by 16.5% in the second quarter. Acrospire Investment Management LLC now owns 705 shares of the medical research company’s stock valued at $109,000 after buying an additional 100 shares during the last quarter. Sun Life Financial INC raised its stake in Laboratory Corporation of America Holdings by 9,200.0% in the second quarter. Sun Life Financial INC now owns 744 shares of the medical research company’s stock valued at $115,000 after buying an additional 736 shares during the last quarter. Parallel Advisors LLC raised its stake in Laboratory Corporation of America Holdings by 377.7% in the first quarter. Parallel Advisors LLC now owns 1,261 shares of the medical research company’s stock valued at $177,000 after buying an additional 997 shares during the last quarter. IFP Advisors Inc raised its stake in Laboratory Corporation of America Holdings by 83.9% in the second quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock valued at $177,000 after buying an additional 523 shares during the last quarter. Finally, Hourglass Capital LLC acquired a new stake in Laboratory Corporation of America Holdings during the second quarter valued at $200,000. Hedge funds and other institutional investors own 93.19% of the company’s stock.

Several equities analysts have weighed in on the stock. Morgan Stanley boosted their target price on shares of Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the company an “overweight” rating in a report on Thursday, August 10th. Barclays PLC upped their price objective on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a report on Thursday, July 27th. Zacks Investment Research raised shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Craig Hallum reaffirmed a “buy” rating and set a $179.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Finally, Credit Suisse Group downgraded shares of Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 target price on the stock. in a research note on Thursday, July 13th. They noted that the move was a valuation call. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $159.75.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.